放射诱导心血管疾病(RICVD)的风险管理:台湾放射肿瘤学会(TASTRO)与台湾心脏学会(TSOC)2022年共识声明
该共识由台湾放射肿瘤学会与台湾心脏学会专家联合制定,聚焦放射诱导心血管疾病(RICVD)的风险分层与临床管理更新,强调多学科协作和心脏肿瘤学项目,以在不影响肿瘤控制的前提下提升对RICVD风险的识别与干预。
要点
- 放射治疗中心脏与血管受照已被视为心血管疾病的新危险因素。
- 共识聚焦RICVD的风险分层与管理,倡导多学科协作和心脏肿瘤学项目。
- 目标是在不危及肿瘤控制的前提下,提升对RICVD风险的认知与干预。
核心结论
- 实施协作性心脏肿瘤学项目下的RICVD管理可改善肿瘤治疗结局并促进高质量临床研究。
研究设计与样本
- 台湾放射肿瘤学会与台湾心脏学会专家共同制定的共识声明,以焦点更新形式提供RICVD风险分层与管理的临床实践建议。
临床应用与阅片要点
- 共识倡导通过多学科专业协作提升对RICVD风险的认知、识别与适当干预。
- 共识认为在协作性心脏肿瘤学项目下实施RICVD管理可改善肿瘤治疗结局。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Advances in cancer management have significantly improved survival in patients with cancers. Cardiovascular complications of cancer treatment are becoming significant competing causes of death in these patients. Radiotherapy is an indispensable component of cancer treatment, and irradiation of the heart and vasculature during cancer radiotherapy is now recognized as a new risk factor for cardiovascular diseases. It is important to involve multidisciplinary expertise and provide practical recommendations to promote awareness, recognize risks, and provide adequate interventions without jeopardizing cancer control. In this consensus paper, experts from the Taiwan Society for Therapeutic Radiology and Oncology and Taiwan Society of Cardiology provide a focused update on the clinical practice for risk stratification and management of radiation-induced cardiovascular disease (RICVD). We believe that implementing RICVD care under a collaborative cardio-oncology program will significantly improve cancer treatment outcomes and will facilitate high quality clinical investigations.
引用
- Lu LS, Wu YW, Chang JT, et al. Risk Management for Radiation-Induced Cardiovascular Disease (RICVD): The 2022 Consensus Statement of the Taiwan Society for Therapeutic Radiology and Oncology (TASTRO) and Taiwan Society of Cardiology (TSOC). Acta Cardiol Sin. 2022. PMID: 35068877. doi:10.6515/ACS.202201_38(1).20211122A
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。